NMRA (STOCKS)
Neumora Therapeutics, Inc. Common Stock
$2.050000
+0.020000 (+0.99%)
Prev close: $2.030000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Paul L. Berns
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $373.18M
- Employees
- 95
- P/E (TTM)
- -1.42
- P/B (TTM)
- 3.46
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
7
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.35 | $-0.33 | -0.0179 | -5.39% |
|
Sep 2025 (Q3)
|
$-0.32 | $-0.34 | +0.0204 | +5.99% |
|
Jun 2025 (Q2)
|
$-0.33 | $-0.38 | +0.0457 | +12.16% |
|
Mar 2025 (Q1)
|
$-0.42 | $-0.38 | -0.0382 | -10.01% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $4.36M |
| Operating Expenses | $241.16M |
| Research and Development | $176.07M |
| Other Operating Expenses | $65.09M |
| Operating Income/Loss | -$241.16M |
| Income/Loss From Continuing Operations After Tax | -$236.93M |
| Income/Loss From Continuing Operations Before Tax | -$236.80M |
| Income Tax Expense/Benefit | $130.00K |
| Interest Expense, Operating | $2.01M |
| Net Income/Loss | -$236.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$236.93M |
| Net Income/Loss Available To Common Stockholders, Basic | -$236.93M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.45 |
| Diluted Earnings Per Share | -$1.45 |
| Basic Average Shares | 163,391,000 |
| Diluted Average Shares | 163,391,000 |
| Assets | $191.05M |
| Current Assets | $190.54M |
| Noncurrent Assets | $510.00K |
| Fixed Assets | $40.00K |
| Other Non-current Assets | $470.00K |
| Liabilities | $87.18M |
| Current Liabilities | $32.45M |
| Accounts Payable | $3.38M |
| Wages | $11.49M |
| Other Current Liabilities | $17.58M |
| Noncurrent Liabilities | $54.73M |
| Long-term Debt | $54.53M |
| Other Non-current Liabilities | $193.00K |
| Equity | $103.87M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $103.87M |
| Liabilities And Equity | $191.05M |
| Net Cash Flow From Operating Activities | -$206.44M |
| Net Cash Flow From Operating Activities, Continuing | -$206.44M |
| Net Cash Flow From Investing Activities | $168.52M |
| Net Cash Flow From Investing Activities, Continuing | $168.52M |
| Net Cash Flow From Financing Activities | $77.09M |
| Net Cash Flow From Financing Activities, Continuing | $77.09M |
| Net Cash Flow | $39.17M |
| Net Cash Flow, Continuing | $39.17M |
| Comprehensive Income/Loss | -$236.99M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$236.99M |
| Other Comprehensive Income/Loss | -$62.00K |